Routine serum C-reactive protein and stroke outcome after intravenous thrombolysis

Acta Neurologica Scandinavica

Volumn 130, Issue 5, 2014, Pages 305-311

  Karlinski, M ^a   Bembenek, J ^a   Grabska, K ^a   Kobayashi, A ^a   Baranowska, A ^a   Litwin, T ^a   Czlonkowska, A ^a,b  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Acute stroke; C reactive protein; Infection; Ischaemic stroke; Outcome; Prognosis; Thrombolysis

Indexed keywords

ALTEPLASE; C REACTIVE PROTEIN; BIOLOGICAL MARKER; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; FEMALE; FIBRINOLYTIC THERAPY; FUNCTIONAL STATUS; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMONIA; PROGNOSIS; PROSPECTIVE STUDY; STROKE PATIENT; URINARY TRACT INFECTION; VERY ELDERLY; BLOOD; CONVALESCENCE; HOSPITALIZATION; MORTALITY; PROCEDURES; REGISTER; RETROSPECTIVE STUDY; STROKE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; FIBRINOLYTIC AGENTS; HOSPITALIZATION; HUMANS; MALE; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; REGISTRIES; RETROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84914170228     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12227     Document Type: Article

References (46)

1. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 2009;40:e380-9.
2. Musunuru K, Kral BG, Blumenthal RS et al. The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med 2008;5:621-35.
3. di Napoli M, Schwaninger M, Cappelli R et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 2005;36:1316-29.
4. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke and mortality: an individual participant meta-analysis. Lancet 2012;375:132-40.
5. Rajeshwar K, Kaul S, Al-Hazzani A et al. C-reactive protein and nitric oxide levels in ischemic stroke and its subtypes: correlation with clinical outcome. Inflammation 2012;35:978-84.
6. di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001;32:917-24.
7. Smith CJ, Emsley HC, Vail A et al. Variability of the systemic acute phase response after ischemic stroke. J Neurol Sci 2006;251:77-81.
8. den Hertog H, van Rossum J, van der Worp H et al. C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death. J Neurol 2009;256:2003-8.
9. Welsh P, Barber M, Langhorne P, Rumley A, Lowe GDO, Stott D. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc Dis 2009;27:247-53.
10. Christensen H, Boysen G. C-reactive protein and white blood cell count increases in the first 24 hours after acute stroke. Cerebrovasc Dis 2004;18:214-9.
11. Idicula TT, Brogger J, Naess H, Waje-Andreassen U, Thomassen L. Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the 'Bergen stroke study'. BMC Neurol 2009;9:1-9.
12. Masotti L, Ceccarelli E, Forconi S, Cappelli R. Prognostic role of C-reactive protein in very old patients with acute ischaemic stroke. J Intern Med 2005;258:145-52.
13. Corso G, Bottacchi E, Brusa A et al. Is there a prognostic role for C-reactive protein in ischemic stroke? Acta Neurol Scand 2010;122:209-16.
14. Song I-U, Kim J-S, Kim Y-I, Lee K-S, Jeong D-S, Chung S-W. Relationship between high-sensitivity C-reactive protein and clinical functional outcome after acute ischemic stroke in a Korean population. Cerebrovasc Dis 2009;28:545-50.
15. Emsley H. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 2003;139:93-101.
16. di Napoli M, Elkind MSV, Godoy DA et al. Role of C-reactive protein in cerebrovascular disease: a critical review. Expert Rev Cardiovasc Ther 2011;9:1565-84.
17. Elkind MSV, Leon V, Moon YP, Paik MC, Sacco RL. High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction. Stroke 2009;40:3233-7.
18. Purroy F, Montaner J, Molina C et al. C-reactive protein predicts further ischemic events in transient ischemic attack patients. Acta Neurol Scand 2007;115:60-6.
19. Elkind MSV, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006;166:2073-80.
20. Muir KW, Weir CJ, Alwan W, Squire IB, Lees K. C-Reactive protein and outcome after ischemic stroke. Stroke 1999;30:981-5.
21. Winbeck K. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 2002;33:2459-64.
22. Grabska K, Gromadzka G, Czlonkowska A. Infections and ischemic stroke outcome. Neurol Res Int 2011;2011:691348.
23. Vermeij F, Scholte op Reimer WJ, de Man P et al. Stroke-associated infection is an independent risk factor for poor outcome after acute ischemic stroke: data from the Netherlands Stroke Survey. Cerebrovasc Dis 2009;27:465-71.
24. Kwan J, Hand P. Infection after acute stroke is associated with poor short-term outcome. Acta Neurol Scand 2007;115:331-8.
25. Jauch E, Saver J, Adams H et al. Guidelines for the early management of patients with acute ischemic stroke. Stroke 2013;44:870-947.
26. Ringleb A, Bousser M-G, Ford G et al. Guidelines for management of ischaemic stroke and transient ischaemic attack. European Stroke Organization guidelines 2009. Cited: 30 June 2013. Available from: http://www.eso-stroke.org/pdf/ESOGuidelines_update_Jan_2009.pdf
27. Salat D, Delgado P, Alonso S et al. Ischemic stroke outcome and early infection: its deleterious effect seems to operate also among tissue plasminogen activator-treated patients. Eur Neurol 2011;65:82-7.
28. Montaner J, Fernandez-Cadenas I, Molina C et al. Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 2006;37:1205-10.
29. Topakian R, Strasak AM, Nussbaumer K, Haring H-P, Aichner FT. Prognostic value of admission C-reactive protein in stroke patients undergoing iv thrombolysis. J Neurol 2008;255:1190-6.
30. Tiainen M, Meretoja A, Strbian D et al. Body temperature, blood infection parameters, and outcome of thrombolysis-treated ischemic stroke patients. Int J Stroke 2013;8:632-8.
31. Wahlgren N, Ahmed N, Dávalos A et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke- Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-82.
32. Hacke W, Kaste M, Brozman M et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29.
33. Polish Office for Registration of Medical Products, Medical Devices and Biochemical Products. Registration of Actilyse in Poland. Cited: 30 June 2013. Available from: http://leki-informacje.pl/lek/charakterystyka-szczegolowa/1489, actilyse-10.html
34. Foulkes M, Wolf P, Price T, Mohr J, Hier D. The Stroke Data Bank: design, methods, and baseline characteristics. Stroke 1988;19:547-54.
35. Hacke W, Kaste M, Fieschi C et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-51.
36. Gumbinger C, Gruschka P, Böttinger M et al. Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage. Stroke 2012;43:240-2.
37. Strbian D, Sairanen T, Meretoja A et al. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology 2011;77:341-8.
38. The NINDS and Stroke RT-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
39. Singh U, Devaraj S, Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 2005;25:2216-21.
40. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis Circulation 2006;113:2135-50.
41. Gill R, Kemp JA, Sabin C, Pepys MB. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J Cereb Blood Flow Metab 2004;24:1214-8.
42. Youn CS, Choi SP, Kim SH et al. Serum highly selective C-reactive protein concentration is associated with the volume of ischemic tissue in acute ischemic stroke. Am J Emerg Med 2012;30:124-8.
43. Ormstad H, Aass H, Lund-Sørensen N, Amthor K-F, Sandvik L. Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. J Neurol 2011;258:677-85.
44. Worthmann H, Tryc A, Goldbecker A et al. The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis 2010;30:85-92.
45. Bikdeli B. C-reactive protein, statins and the risk of vascular events: a better understanding. Cardiovasc Drug Ther 2011;25:545-9.
46. Thanvi BR, Treadwell S, Robinson T. Haemorrhagic transformation in acute ischaemic stroke following thrombolysis therapy: classification, pathogenesis and risk factors. Postgrad Med J 2008;84:361-7.